Squarepoint
INBX icon

Squarepoint’s Inhibrx INBX Stock Holding History

Squarepoint’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-6,543
Closed -$620K – 4712
2026
Q2 		$620K Sell
6,543
-9,096
-58% -$911K ﹤0.01% 3256
2026
Q1 		$1.05M Buy
15,639
+12,241
+360% +$908K ﹤0.01% 2738
2025
Q4 		$268K Buy
+3,398
New +$232K ﹤0.01% 3685
2024
Q4 		– Sell
-21,066
Closed -$330K – 5246
2024
Q3 		$330K Buy
+21,066
New +$296K ﹤0.01% 3385

Other funds holding INBX

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Capitolis Liquid Global Markets
Capitolis Liquid Global Markets New York $22.4B AUM 40.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Squarepoint's INBX Position: Q3 2026 in Review

Squarepoint sold out of Inhibrx (INBX) in Q3 2026, closing a stake of 6,543 shares — an estimated $620K sold.

Squarepoint first reported a position in INBX in Q3 2024 and held it in 4 quarters. The position peaked at $1.05M in Q1 2026. 89 funds tracked by Wall St. Rank hold INBX as of Q3 2026.

  • Squarepoint reported no remaining Inhibrx position as of Q3 2026 after selling out during the quarter.
  • Squarepoint sold 6,543 Inhibrx shares in Q3 2026, an estimated $620K.
  • Squarepoint first reported a position in Inhibrx in Q3 2024 and held it in 4 quarters.
  • Squarepoint's Inhibrx position peaked at $1.05M in Q1 2026.
  • 89 funds tracked by Wall St. Rank held Inhibrx as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.